Cancer biomarkers: knowing the present and predicting the future.

In recent years the discovery of cancer biomarkers has become a major focus of cancer research. The widespread use of prostate-specific antigen in prostate cancer screening has motivated researchers to identify suitable markers for screening different types of cancer. Biomarkers are also useful for diagnosis, monitoring disease progression, predicting disease recurrence and therapeutic treatment efficacy. With the advent of new and improved genomic and proteomic technologies such as DNA and tissue microarray, two-dimensional gel eletrophoresis, mass spectrometry and protein assays coupled with advanced bioinformatic tools, it is possible to develop biomarkers that are able to reliably and accurately predict outcomes during cancer management and treatment. In years to come, a serum or urine test for every phase of cancer may drive clinical decision making, supplementing or replacing currently existing invasive techniques.

[1]  T. Turpeenniemi‐Hujanen,et al.  Matrix metalloproteinase‐2 immunoreactive protein , 1998, Cancer.

[2]  H. Sutton,et al.  Effect of external beam radiation therapy on serum prostate-specific antigen. , 1990, Urology.

[3]  M. Loda,et al.  Thymosin β15: A novel regulator of tumor cell motility upregulated in metastatic prostate cancer , 1996, Nature Medicine.

[4]  X. Guan,et al.  Prognostic significance of c‐myc and AIB1 amplification in hepatocellular carcinoma , 2002, Cancer.

[5]  M. Kitaichi,et al.  Caspase-3 Expression in Human Gastric Carcinoma and Its Clinical Significance , 2004, Oncology.

[6]  S. P. Fodor,et al.  High density synthetic oligonucleotide arrays , 1999, Nature Genetics.

[7]  A. Godwin,et al.  DNA array‐based method for detection of large rearrangements in the BRCA1 gene , 2002, Genes, chromosomes & cancer.

[8]  M. Rubin,et al.  Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. , 2001, Neoplasia.

[9]  T. Poggio,et al.  Multiclass cancer diagnosis using tumor gene expression signatures , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  S. Gygi,et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.

[11]  F. Mostofi,et al.  Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. , 1996, Surgery.

[12]  E. Petricoin,et al.  Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. , 2003, Advances in experimental medicine and biology.

[13]  M. Dewhirst,et al.  Circulating D‐dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma , 2004, Cancer.

[14]  Kathleen N Lohr,et al.  Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force , 2002, Annals of Internal Medicine.

[15]  T. Čufer,et al.  Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients. , 2002, Clinical breast cancer.

[16]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[17]  A. Partin,et al.  Prostate cancer: detection, staging, and treatment of localized disease. , 1999, Seminars in roentgenology.

[18]  Phil Gold,et al.  SPECIFIC CARCINOEMBRYONIC ANTIGENS OF THE HUMAN DIGESTIVE SYSTEM , 1965, The Journal of experimental medicine.

[19]  N. Weidner,et al.  Determination of epidermal growth factor receptor provides additional prognostic information to measuring tumor angiogenesis in breast carcinoma patients , 2004, Breast Cancer Research and Treatment.

[20]  E. Petricoin,et al.  Early detection: Proteomic applications for the early detection of cancer , 2003, Nature Reviews Cancer.

[21]  J. Foekens,et al.  Prognostic significance of cathepsins B and L in primary human breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Grignon,et al.  Diagnostic and prognostic markers for human prostate cancer , 1997, The Prostate.

[23]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[24]  A. Chambers,et al.  The Role of Osteopontin in Breast Cancer: Clinical and Experimental Studies , 2001, Journal of Mammary Gland Biology and Neoplasia.

[25]  N. Fedarko,et al.  Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  E. Petricoin,et al.  Clinical potential of proteomics in the diagnosis of ovarian cancer , 2002, Expert review of molecular diagnostics.

[27]  E. Kohn,et al.  Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer , 2002, Proteomics.

[28]  C. Paweletz,et al.  New approaches to proteomic analysis of breast cancer , 2001, Proteomics.

[29]  G. Hortobagyi,et al.  Ki‐67 immunostaining in node‐negative stage I/II breast carcinoma. Significant correlation with prognosis , 1991, Cancer.

[30]  A. Carothers,et al.  Microsatellite instability and the role of hMSH2 in sporadic colorectalcancer. , 1996, Oncogene.

[31]  K. Kinzler,et al.  Serial Analysis of Gene Expression , 1995, Science.

[32]  C. Haglund,et al.  Expression of Trypsinogen-1, Trypsinogen-2, and Tumor-Associated Trypsin Inhibitor in Ovarian Cancer , 2004, Clinical Cancer Research.

[33]  T. Isono,et al.  Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. , 2004, Clinical chemistry.

[34]  D. McCarthy,et al.  Serum Protein Expression Profiling for Cancer Detection: Validation of a SELDI-Based Approach for Prostate Cancer , 2004, Disease markers.

[35]  S. Gygi,et al.  Quantitative Cancer Proteomics: Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) as a Tool for Prostate Cancer Research*S , 2004, Molecular & Cellular Proteomics.

[36]  Arul M Chinnaiyan,et al.  Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. , 2003, Journal of the National Cancer Institute.

[37]  N. Ragni,et al.  Overexpression of Cyclin D1 Is Associated with Poor Survival in Epithelial Ovarian Cancer , 2004, Oncology.

[38]  D. Ornstein,et al.  Proteomics to diagnose human tumors and provide prognostic information. , 2004, Oncology.

[39]  Dennis C. Sgroi,et al.  Laser Capture Microdissection and Advanced Molecular Analysis of Human Breast Cancer , 2003, Journal of Mammary Gland Biology and Neoplasia.

[40]  Michael W Kattan,et al.  The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  E Mahlamäki,et al.  Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. , 1999, Journal of the National Cancer Institute.

[42]  Ming-Hui Chen,et al.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2004, The New England journal of medicine.

[43]  R. L. Baldwin,et al.  Differential gene expression between normal and tumor-derived ovarian epithelial cells. , 2000, Cancer research.

[44]  F. Christians,et al.  Induction of GADD45 and JNK/SAPK-Dependent Apoptosis following Inducible Expression of BRCA1 , 1999, Cell.

[45]  A W Partin,et al.  Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.

[46]  O. Nanni,et al.  HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  P. Lipponen,et al.  Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. , 1997, European urology.

[48]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[49]  A. Chambers,et al.  Role of osteopontin in tumour progression , 2004, British Journal of Cancer.

[50]  P. Brown,et al.  Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A. Avilés,et al.  Beta-2 microglobulin and lactate dehydrogenase levels are useful prognostic markers in early stage primary gastric lymphoma. , 1998, Clinical and Laboratory Haematology.

[52]  Nan Hu,et al.  2D Differential In-gel Electrophoresis for the Identification of Esophageal Scans Cell Cancer-specific Protein Markers* , 2002, Molecular & Cellular Proteomics.

[53]  G. Torre,et al.  Serum levels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases. , 1991, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[54]  L. Kiemeney,et al.  Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer. , 2000, Urology.

[55]  S. P. Fodor,et al.  Light-directed, spatially addressable parallel chemical synthesis. , 1991, Science.

[56]  R. Todd,et al.  Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis , 2001, Oncogene.

[57]  J. Moul.  Prostate specific antigen only progression of prostate cancer. , 2000, The Journal of urology.

[58]  G M Clark,et al.  How to use prognostic factors in axillary node-negative breast cancer patients. , 1990, Journal of the National Cancer Institute.

[59]  B. Haab,et al.  Advances in protein microarray technology for protein expression and interaction profiling. , 2001, Current opinion in drug discovery & development.

[60]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[61]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[62]  Jeffrey S. Morris,et al.  Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments , 2004, Bioinform..

[63]  M. Barry.  Prostate-Specific–Antigen Testing for Early Diagnosis of Prostate Cancer , 2001 .

[64]  V. Sharov,et al.  Identification of tumor markers in models of human colorectal cancer using a 19,200-element complementary DNA microarray. , 2001, Cancer research.

[65]  B. Zetter,et al.  Sensitivity to polyamine-induced growth arrest correlates with antizyme induction in prostate carcinoma cells. , 1999, Cancer research.

[66]  B. Zetter,et al.  Type XXIII Collagen, a New Transmembrane Collagen Identified in Metastatic Tumor Cells* , 2003, Journal of Biological Chemistry.

[67]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[68]  Peter F M Choong,et al.  Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. , 2003, Clinical orthopaedics and related research.

[69]  Phil Gold,et al.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES , 1965, The Journal of experimental medicine.

[70]  D. Cunningham,et al.  Markers, markers everywhere..... Prognosis in colorectal cancer--time for a new approach. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  T. Stamey.  Preoperative serum prostate-specific antigen (PSA) below 10 microg/l predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure. , 2001, Clinical chemistry.

[72]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[73]  F. Ece,et al.  The value of Ca 125 in the evaluation of tuberculosis activity. , 2001, Respiratory medicine.

[74]  Katie L Meehan,et al.  Quantitative profiling of LNCaP prostate cancer cells using isotope‐coded affinity tags and mass spectrometry , 2004, Proteomics.

[75]  F Pozza,et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.

[76]  J. Nikliński,et al.  Prognostic molecular markers in non-small cell lung cancer. , 2001, Lung cancer.

[77]  S. Wells,et al.  Carcinoembryonic antigen and calcitonin as markers of malignancy in medullary thyroid carcinoma. , 1979, Surgical forum.

[78]  S. Loening,et al.  Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? , 2000, Clinical chemistry.

[79]  T. Gasser,et al.  Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. , 2004, The Journal of urology.

[80]  H. Moch,et al.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.

[81]  J. Schulte‐Mönting,et al.  Ki‐67 immunostaining in human breast tumors and its relationship to prognosis , 1991, Cancer.

[82]  E. Diamandis.  Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? , 2003, Clinical chemistry.

[83]  B. Konety,et al.  Urine based markers of urological malignancy. , 2002, The Journal of urology.

[84]  J. Risteli,et al.  Comparison of carboxyterminal telopeptide of type I collagen (ICTP) and CA 125 as predictors of prognosis in ovarian cancer. , 2004, Anticancer research.

[85]  H. Moch,et al.  High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. , 1999, The American journal of pathology.

[86]  M. Bittner,et al.  Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. , 1998, Cancer research.

[87]  D. Schaid,et al.  Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. , 1999, Journal of the National Cancer Institute.

[88]  Peter Boyle,et al.  Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. , 2001 .

[89]  Anna Frolov,et al.  The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. , 2003, Cancer research.

[90]  B. Têtu,et al.  Prognostic significance of HER‐2/neu oncoprotein expression in node‐positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy , 1994, Cancer.

[91]  M. Loda,et al.  Thymosin β15 expression in tumor cell lines with varying metastatic potential , 1998, Clinical & Experimental Metastasis.